Colon to Rectum

Lancet. 2023;402(10412):1552–61

Jalava K, Sallinen V, Lampela H, Malmi H, Steinholt I, Augestad KM, Leppäniemi A, Mentula P

Role of preoperative in-hospital delay on appendiceal perforation while awaiting appendicectomy (PERFECT): A Nordic, pragmatic, open-label, multicenter, non-inferiority, randomized controlled trial


Background: Appendicectomy remains the standard treatment for appendicitis. No international consensus exists on the surgical urgency for acute uncomplicated appendicitis, and recommendations vary from surgery without delay to surgery within 24 hours. Longer in-hospital delay has been thought to increase the risk of perforation and further morbidity. Therefore, the authors aimed to compare the rate of appendiceal perforation in patients undergoing appendicectomy scheduled to 2 different urgencies (< 8 h vs. < 24 h).
Methods: In this pragmatic, open-label, multicenter, non-inferiority, parallel, randomized controlled trial in 2 hospitals in Finland and 1 in Norway, patients (aged ≥ 18 years) with presumed uncomplicated acute appendicitis were randomly assigned (1:1) to an appendicectomy scheduled within 8 hours or within 24 hours to determine whether longer in-hospital delay (time between randomization and surgical incision) is not inferior to shorter delay. Patients were excluded in cases of pregnancy, suspicion of perforated appendicitis (C-reactive protein level of ≥ 100 mg/l, fever > 38.5 °C, signs of complicated appendicitis on imaging studies, or clinical generalized peritonitis), or other reasons requiring prompt surgery. The recruiters were on-duty surgeons who decided to proceed with the appendicectomy. The randomization sequence was generated using block randomization with randomly varying block sizes and stratified by hospital districts; neither physicians nor patients were masked to group assignment. The primary outcome was perforated appendicitis diagnosed during surgery analyzed in all patients who received an appendicectomy by intention to treat. The absolute difference in rates of perforated appendicitis was compared between the groups. Complications and other safety outcomes were analyzed in all patients who received an appendicectomy. A margin of 5 percentage points was used to establish non-inferiority.
Findings: Between May 18, 2020, and December 31, 2022, 2095 patients were assessed for eligibility, of whom 1822 were randomly assigned to appendicectomy scheduled within 8 hours (n = 914) or 24 hours (n = 908). After randomization, 19 of 1822 patients (1%) were excluded due to protocol violation. 1803 patients were included in the intention-to-treat analyses, 985 (55%) of whom were male and 818 (45%) female. Appendiceal perforation rate was similar between groups (77/907 patients [8%] assigned to the < 8 h group and 81/896 patients [9%] assigned to the < 24 h group; absolute risk difference 0.6%, 95% confidence interval [CI]: -2.1–3.2, p = 0.68; risk ratio = 1.065, 95% CI: 0.790–1.435). No significant difference was found between the complication rates within 30 days (66/907 patients [7%] in the < 8 h group vs. 56/896 patients [6%] in the < 24 h group; difference -1.0%, 95% CI: -3.3–1.3; p = 0.39), and no deaths occurred during this follow-up period.

Interpretation: In patients with presumed uncomplicated acute appendicitis, scheduling appendicectomy within 24 hours does not increase the risk of appendiceal perforation compared with scheduling appendicectomy within 8 hours. The results can be used to allocate operating room resources, for example postponing night-time appendicectomy to daytime.

Dr. P. Mentula, Department of Gastroenterological Surgery, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, E-Mail: panu.mentula@hus.fi

DOI: 10.1016/s0140-6736(23)01311-9

Back to overview

this could be of interest:

Impact of submucosal saline injection during cold snare polypectomy for colorectal polyps sized 3–9 mm: A multicenter randomized controlled trial

Am J Gastroenterol. 2023;118(10):1848–54

Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): A randomized, double-blind, placebo-controlled, phase 3 trial

Lancet. 2023;402(10414):1773–85

More articles on the topic